Navigating the Crossroads of Diabetes and Chronic Opioid Therapy: Differentiating Hypoglycemia from Opioid Withdrawal

Abstract

Get full access to this article

View all access options for this article.

References

Rickels

MR.

Hypoglycemia-associated autonomic failure, counterregulatory responses, and therapeutic options in type 1 diabetes. Ann N Y Acad Sci. 2019;1454(1):68-79. doi:10.1111/nyas.14214

Kosten

Baxter

LE.

Effective management of opioid withdrawal symptoms: a gateway to opioid dependence treatment. Am J Addict. 2019;28(2):55-62. doi:10.1111/ajad.12862

Malboosbaf

Hatami

Maghsoomi

Methadone-induced hypoglycemia: a case report. J Diabetes Investig. 2022;14(1):145-146. doi:10.1111/jdi.13919

Srinivasan

Dutta

Bansal

, et al. Efficacy and safety of low-dose naltrexone in painful diabetic neuropathy: a randomized, double-blind, active-control, crossover clinical trial. J Diabetes. 2021;13(10):770-778. doi:10.1111/1753-0407.13202

Butler

Budman

Fernandez

, et al. Development and validation of the Current Opioid Misuse Measure. Pain. 2007;130(1-2):144-156. doi:10.1016/j.pain.2007.01.014

Powers

Bardsley

Cypress

, et al. Diabetes self-management education and support in adults with type 2 diabetes: a consensus report. Diabetes Care. 2020;43(7):1636-1649. doi:10.2337/dci20-0023

McCall

Lieb

Gianchandani

, et al. Management of individuals with diabetes at high risk for hypoglycemia: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2023;108(3):529-562. doi:10.1210/clinem/dgac596

Diabetes Care. Standards of Care in Diabetes—2025: facilitating positive health behaviors and glycemic goals. Diabetes Care. 2025;48(suppl 1):S86-S145. doi:10.2337/dc25-S005